The Past, Present, and Future of a Human T-Cell Leukemia Virus Type 1 Vaccine

Keyphrases

• Futures Past 100%
• Past-present 100%
• Human T-cell Leukemia Virus Type 1 (HTLV-1) 100%
• Adult T-cell Leukemia 27%
• Disease Development 18%
• Vaccine Development 18%
• HTLV-1-associated Myelopathy 18%
• Treatment Options 9%
• Virus 9%
• Therapeutic Intervention 9%
• Poor Prognosis 9%
• CD4+ T 9%
• New Therapeutics 9%
• Molecular Tools 9%
• Progressive Neurodegeneration 9%
• Associated Diseases 9%
• Epidemiological Data 9%
• Development Effort 9%
• Long-term Treatment 9%
• Infected Individual 9%
• Palliative Care 9%
• Human Retrovirus 9%
• Limited Treatment Options 9%
• Myelopathy 9%
• Tropical Spastic Paraparesis 9%
• Preventive Vaccine 9%
• Cell Malignancy 9%

Medicine and Dentistry

• Human T-Lymphotropic Virus 1 100%
• Tropical Spastic Paraparesis 45%
• Adult T-Cell Leukemia/Lymphoma 27%
• Infection 18%
• Disease Course 18%
• Vaccine Development 18%
• Diseases 18%
• T-Helper Cell 9%
• Cancer 9%
• Symptomatic Treatment 9%
• Degenerative Disease 9%
• Retroviridae 9%
• Spinal Cord Disease 9%
• Virus 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Human T-Lymphotropic Virus 1 100%
• Tropical Spastic Paraparesis 45%
• T Cell Leukemia 27%
• Infection 18%
• Disease Course 18%
• Vaccine Development 18%
• Diseases 18%
• Degenerative Disease 9%
• Retrovirus 9%
• Spinal Cord Disease 9%